Table 1.
Age, years | |
Median (range) | 55.0 (35-75) |
ECOG PS, n (%) | |
0 | 39 (76) |
1 | 12 (24) |
2 | 0 |
Disease type, n (%) | |
Invasive carcinoma NOS | 41 (80) |
Papillary tubular carcinoma | 9 (18) |
Invasive lobular carcinoma | 1 (2) |
Time since diagnosis (months) (n = 44) | |
Minimum | 10 |
1st quartile | 24.5 |
Median | 45.6 |
3rd quartile | 68.2 |
Maximum | 137 |
Disease stage at the initial diagnosis, n (%) | |
I | 1 (2) |
II | 20 (39) |
III | 21 (41) |
IV | 6 (12) |
Unknown | 3 (6) |
Prior anti-cancer therapy, n (%) | |
Chemotherapy | 51 (100) |
Anthracyclines | 51 (100) |
Taxanes | 51 (100) |
Trastuzumab | 51 (100) |
Surgery | 46 (90) |
Radiotherapy | 28 (55) |
Endocrine therapy | 20 (39) |
Vaccines | 0 |
Immunotherapy | 0 |
Duration from completion of trastuzumab, n (%) (weeks) | |
<8 | 40 (78) |
≥8 | 11 (22) |
Number of metastatic sites, n (%) | |
≥3 | 21 (41) |
2 | 19 (37) |
1 | 11 (22) |
Visceral or nonvisceral metastatic, n (%) | |
Visceral | 42 (82) |
Nonvisceral | 9 (18) |
Hormone receptor status, n (%) | |
ER+ and/or PgR+ | 15 (29) |
ER+ and PgR+ | 7 (14) |
ER+ and PgR− | 8 (16) |
ER− and PgR− | 35 (69) |
Unknown | 1 (2) |
ER estrogen receptor, PgR progesterone receptor